APA (7th ed.) Citation

DePaoli, A., Bashir, M., Phung, V., Yan, A., Ling, L., Baxter, B., & Tian, H. (2019). PS-108-NGM, a novel activator of beta-Klotho/FGFR1c: A single dose significantly reduces steatosis (liver fat by MRI-PDFF), inflammation (ALT, AST) and fibrogenic activity (Pro-C3) in NAFLD subjects. Journal of hepatology, 70(1), e68-e69. https://doi.org/10.1016/S0618-8278(19)30120-3

Chicago Style (17th ed.) Citation

DePaoli, Alex, Mustafa Bashir, Van Phung, Andrew Yan, Lei Ling, Bryan Baxter, and Hui Tian. "PS-108-NGM, a Novel Activator of Beta-Klotho/FGFR1c: A Single Dose Significantly Reduces Steatosis (liver Fat by MRI-PDFF), Inflammation (ALT, AST) and Fibrogenic Activity (Pro-C3) in NAFLD Subjects." Journal of Hepatology 70, no. 1 (2019): e68-e69. https://doi.org/10.1016/S0618-8278(19)30120-3.

MLA (9th ed.) Citation

DePaoli, Alex, et al. "PS-108-NGM, a Novel Activator of Beta-Klotho/FGFR1c: A Single Dose Significantly Reduces Steatosis (liver Fat by MRI-PDFF), Inflammation (ALT, AST) and Fibrogenic Activity (Pro-C3) in NAFLD Subjects." Journal of Hepatology, vol. 70, no. 1, 2019, pp. e68-e69, https://doi.org/10.1016/S0618-8278(19)30120-3.